Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | GYS1 | P13807 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3275405 | 1.00 | MET (0.55) | METALKSPHK2NR4A2MAOB | |
| SCHEMBL3279731 | 0.95 | MET (0.58) | METALKSPHK2NR4A2MAOB | |
| SCHEMBL3279727 | 0.95 | MET (0.58) | METALKSPHK2NR4A2MAOB | |
| Trifluoroacetic Acid SCHEMBL3275018 | 0.90 | SPHK2 (0.53) | METALKSPHK2MAOBHRH3 | |
| Trifluoroacetic Acid SCHEMBL5498247 | 0.90 | HRH3 (0.58) | METALKSPHK2NR4A2MAOB | |
| Trifluoroacetic Acid SCHEMBL5498248 | 0.90 | HRH3 (0.58) | METALKSPHK2NR4A2MAOB | |
| Trifluoroacetic Acid SCHEMBL3275015 | 0.90 | SPHK2 (0.53) | METALKSPHK2MAOBHRH3 | |
| Trifluoroacetic Acid SCHEMBL5506854 | 0.90 | HRH3 (0.57) | METALKSPHK2HRH3SPHK1 | |
| Trifluoroacetic Acid SCHEMBL3275399 | 0.90 | HRH3 (0.57) | METALKSPHK2HRH3SPHK1 | |
| Trifluoroacetic Acid SCHEMBL12095860 | 0.90 | HRH3 (0.56) | METALKSPHK2HRH3SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | claimed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | MET 903/4885ALK 1133/4885SPHK2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.